Stock Taper 
AZN
$162.70
▼ DOWN 1.11% (-1.82)
KEY STATISTICS
Market Cap$252.33 B
52w High$212.71
52w Low$145.80
Dividend Yield1.21%
FrequencySemi-Annual
P/E17.57
Volume2.88M
Shares Out.1.55B
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Pascal Claude Roland Soriot
ABOUT
SECTOR
Healthcare
WENT PUBLIC
May 12, 1993
METHOD OF GOING PUBLIC
Dual Listing
FULL TIME EMPLOYEES
96,100
PRICE TARGET
Target High$216.00
Target Low$158.00
Target Median$185.00
Target Consensus$186.67
UPCOMING EARNINGS
DateOct 30, 2026
DayFriday
Rev. Est.$16.05B
OCT
30
FRI
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-02-02 | Reverse | 1:2 |
| 2015-07-27 | Forward | 2:1 |
| 1998-04-08 | Forward | 3:1 |
PRICE
$162.70 ▼ DOWN 1.11% (−$1.82)About AstraZeneca PLC
https://www.astrazeneca.com ↗AstraZeneca PLC is a global biopharmaceutical company developing and commercializing medicines for cardiovascular, oncology, and rare diseases, with a broad portfolio and collaborations in drug discovery and AI technologies.
INDUSTRY
Drug Manufacturers - General
A PRODUCT ASTRAZENECA PLC IS KNOWN FOR
Tagrisso (osimertinib)
Tagrisso, a targeted therapy for genetically mutated non-small cell lung cancer, is a key AstraZeneca oncology product, driving revenue and establishing itself as a standard of care in innovative cancer treatment.
Revenue by Products
| Icon | PRODUCT | Q2-2019 | Q2-2021 | Q2-2022 | Q2-2023 |
|---|---|---|---|---|---|
 | Total Oncology | — | — | $1.6B | $4.38B ▲ |
 | Oncology Products | $2.17B | $3.29B ▲ | — | — |
 | Cardiovascular Renal And Metabolism Products | $1.66B | $2.02B ▲ | — | — |
 | Farxiga | $377M | $732M ▲ | $275M ▼ | $1.5B ▲ |
 | Tagrisso | $784M | $1.31B ▲ | $513M ▼ | $1.49B ▲ |
 | BioPharmaceuticals total Respiratory Immunology | — | — | $654M | $1.48B ▲ |
 | Respiratory Products | $1.25B | $1.42B ▲ | — | — |
 | Imfinzi | $338M | $604M ▲ | $374M ▼ | $1.08B ▲ |
 | Covid19 | — | $862M | — | — |
 | Covid19 Vaccine Astrazeneca C19vaz | — | $862M | — | — |
 | Soliris | — | — | $574M | $814M ▲ |
 | Lynparza | $283M | $588M ▲ | $312M ▼ | $717M ▲ |
 | Ultomiris | — | — | $236M | $713M ▲ |
 | Calquence | $64M | $280M ▲ | $396M ▲ | $653M ▲ |
 | Symbicort | $585M | $680M ▲ | $222M ▼ | $600M ▲ |
 | Other Products | $641M | $454M ▼ | — | — |
 | Fasenra | $167M | $320M ▲ | $230M ▼ | $406M ▲ |
 | Brilinta | $389M | $375M ▼ | $185M ▼ | $331M ▲ |
 | Total Other medicines | — | — | $36M | $301M ▲ |
 | Strensiq | — | — | $193M | $300M ▲ |
 | Crestor | $310M | $265M ▼ | $16M ▼ | $280M ▲ |
 | Nexium | $393M | $336M ▼ | $30M ▼ | $248M ▲ |
 | Zoladex | $197M | $244M ▲ | $3M ▼ | $233M ▲ |
 | SelokenToprolXL | $168M | $266M ▲ | $223M ▼ | $164M ▼ |
 | Breztri | — | $56M | $53M ▼ | $163M ▲ |
 | Other Respiratory Products | $71M | $130M ▲ | — | — |
 | Pulmicort | $333M | $167M ▼ | $15M ▼ | $124M ▲ |
 | Lokelma | — | $39M | $39M | $100M ▲ |
 | Synagis | $96M | $24M ▼ | $2M ▼ | $87M ▲ |
 | Koselugo | — | $1M | $47M ▲ | $80M ▲ |
 | Faslodex | $267M | $105M ▼ | $5M ▼ | $78M ▲ |
 | Roxadustat | — | $51M | $50M ▼ | $73M ▲ |
 | Respiratory Others | — | — | $46M | $71M ▲ |
 | Saphnelo | — | — | $23M | $68M ▲ |
 | Enhertu | — | $3M | $18M ▲ | $67M ▲ |
 | Onglyza | $116M | $99M ▼ | $22M ▼ | $65M ▲ |
 | Oncology Others | — | — | $1M | $54M ▲ |
 | Other Others | — | — | $6M | $53M ▲ |
 | Other Cardiovascular Renal And Metabolism Products | $68M | $47M ▼ | — | — |
 | Movantik Moventig | $47M | — | — | — |
 | Kanuma | — | — | $20M | $46M ▲ |
 | Losec Prilosec | $68M | $46M ▼ | — | — |
 | Andexxa | — | — | $18M | $45M ▲ |
 | Bydureon | $141M | $95M ▼ | $62M ▼ | $43M ▼ |
 | Vaxzevria | — | — | — | $28M |
 | Arimidex | $60M | $29M ▼ | $28M ▼ | — |
 | Other Products Others | $30M | $26M ▼ | — | — |
 | Atacand | $56M | $23M ▼ | — | — |
 | Casodex | $57M | $41M ▼ | $21M ▼ | — |
 | Seroquel Xr Ir | $32M | $21M ▼ | — | — |
 | DalirespDaxas | $56M | $54M ▼ | $54M | $17M ▼ |
 | Byetta | $25M | $16M ▼ | — | — |
 | Bevespi | $20M | $13M ▼ | $11M ▼ | $15M ▲ |
 | Other Diabetes | — | $15M | — | — |
 | Symlin | $15M | — | — | — |
 | Other Oncology Products | $28M | $13M ▼ | — | — |
 | Tudorza Eklira | $13M | — | — | — |
 | FluMist | — | $2M | $1M ▼ | $3M ▲ |
 | Iressa | $118M | $47M ▼ | $2M ▼ | — |
 | Duaklir | $1M | — | — | — |
Revenue by Geography
| Map | REGION | FY2025 |
|---|---|---|
 | The Americas | $27.56B |
 | Europe excluding the United Kingdom | $13.46B |
 | Asia Africa And Australasia | $13.37B |
 | UNITED KINGDOM | $4.36B |
ETFS HOLDING THIS STOCK
ETFS HOLDING
116
LISTED HERE
26
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
25.87%
HOLDERS
2,106
TOP 12 OF 2,106 · RANKED BY POSITION SIZE
Investor Ab
Price T Rowe Associates Inc /Md/
Primecap Management Co/Ca/
Capital International Investors
Norges Bank
Bank Of America Corp /De/
Wellington Management Group Llp
Capital World Investors
Fmr LLC
Legal & General Group Plc
Fisher Asset Management, LLC
Franklin Resources Inc
RATINGS SNAPSHOT
Overall rating: B+
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score3
TRADES BY CONGRESS
HOUSE TRADES
Gilbert Cisneros
Purchase
2025-12-18
Julia Letlow
Purchase
2025-12-08
Lisa McClain
Sale
2025-10-31
Valerie Hoyle
Sale (Full)
2025-09-23
INSIDER TRADES
★
OFFICER: SVP, GROUP CONTROLLER
Sharma Mani
Purchase · 2 shares
2026-08-06
★
OFFICER: SEE REMARKS
Sharma Mani
Purchase · 2 shares
2026-07-06
★
OFFICER: SEE REMARKS
Sharma Mani
Purchase · 1 shares
2026-06-08
★
OFFICER: SEE REMARKS
Sharma Mani
Sale · 11.9K shares
2026-05-20
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 LLY | $1172.86 | COMPARE |
 JNJ | $268.04 | COMPARE |
 ABBV | $255.48 | COMPARE |
 MRK | $148.26 | COMPARE |
 NVS | $153.81 | COMPARE |
 AMGN | $432.42 | COMPARE |
 GILD | $145.68 | COMPARE |
 PFE | $27.96 | COMPARE |